← Oncology Approval Tracker

FDA DECISION ·

Tepmetko

tepotinib · EMD Serono

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Feb 15, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations.

LAMPGEN ANALYSIS

Why it matters

The decision creates a MET-targeted option for a defined metastatic lung cancer population. FDA later granted traditional approval on February 15, 2024.

What research teams should watch

Document the MET exon 14 result and assay, and capture edema and dose interruptions.

PRIMARY RECORDS

Sources